Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Biomea Fusion ( (BMEA) ).
On January 14, 2026, Biomea Fusion presented updated data on its diabetes and obesity pipeline at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and concurrently refreshed its corporate presentation for ongoing use with investors and analysts. The company highlighted clinical and preclinical results for its lead candidate icovamenib, showing that a 12-week dosing regimen in severe insulin-deficient type 2 diabetes patients produced durable reductions in HbA1c and increased insulin secretion measured by C-peptide index up to nine months after treatment ended, alongside evidence of enhanced beta-cell mass and function and improved GLP-1 receptor and insulin transcript levels in human islets, with a generally favorable safety profile and low rates of serious adverse events, underscoring its bid to differentiate in a crowded diabetes market by targeting disease progression rather than symptoms.
The most recent analyst rating on (BMEA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Biomea Fusion stock, see the BMEA Stock Forecast page.
Spark’s Take on BMEA Stock
According to Spark, TipRanks’ AI Analyst, BMEA is a Neutral.
The score is primarily held down by weak financial performance (no revenue, large losses, and ongoing cash burn with a shrinking equity base) and a downtrend technically (price below key moving averages). Positive corporate events (Phase II results and financing) provide some offset, but valuation remains constrained by persistent losses.
To see Spark’s full report on BMEA stock, click here.
More about Biomea Fusion
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for metabolic diseases, including type 2 diabetes and obesity. Its pipeline includes icovamenib, a selective and partial menin inhibitor in Phase 2 trials for insulin-deficient type 2 diabetes patients inadequately controlled on GLP-1 therapies, and BMF-650, an oral GLP-1 receptor agonist in Phase 1 development for weight loss in obese patients.
Average Trading Volume: 1,439,247
Technical Sentiment Signal: Sell
Current Market Cap: $103.2M
For a thorough assessment of BMEA stock, go to TipRanks’ Stock Analysis page.